Sionna Therapeutics, Inc.
NASDAQ:SIONBiotechnology
+$0.68 today
- Market cap
- $134.35M
- Beta
- 1.29
- P/E (TTM)
- -19.7
- EPS (TTM)
- -$1.90
Volume 0.52M
Average 0.39M
SION Operating Cash Flow
Cash generated by the company's core business operations during the period.
Sionna Therapeutics, Inc.NASDAQ: SION
Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Operating cash flow growth accelerates
Q1 FY2026 operating cash flow of $21.84M (cash outflow) rose 34.1% year over year, ahead of the +28.5% change in trailing-twelve-month operating cash flow. Sequentially, it rose 31.4% from the prior quarter. Over 3 fiscal years it compounded at +22.5% a year.
Context
- Operating cash flow grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +34.1% holds above the trailing-twelve-month pace of +28.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (66.3M) USD
- Year-over-year change
- -25.6%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (66.3M) | -25.6% |
| FY2024 | 2024-12-31 | (52.79M) | -20.8% |
| FY2023 | 2023-12-31 | (43.7M) | -21.2% |
| FY2022 | 2022-12-31 | (36.07M) | — |
Operating Cash Flow vs competitors
How SION compares with its peers on the latest reported figures
- SION's LTM Mar 2026 operating cash flow of $71.85M is the 9th largest of the 11 companies compared; the peer median is $116.61M.
- Its year-over-year change of +28.5% is the 6th highest of 11, against a peer median of +32.1%.
- Over three fiscal years its annual growth of +22.5% compares with a peer median of +26.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $511.4M | -20.7% | +27.0% | — | |
| LTM Jun 2026 | $338.65M | +82.8% | +52.8% | — | |
| LTM Sep 2026 | $251.97M | +40.4% | +26.7% | 224975.9% | |
| LTM Sep 2026 | $229.03M | +23.8% | +88.1% | — | |
| LTM Mar 2026 | $121.54M | -273.9% | +4.1% | 607.7% | |
| LTM Sep 2026 | $111.69M | +73.8% | — | 42.0% | |
| LTM Mar 2026 | $77.55M | +68.6% | +24.2% | 358.8% | |
| LTM Sep 2026 | $75.22M | -28.1% | — | 110.8% | |
| LTM Mar 2026 | $71.85M | +28.5% | +22.5% | — | |
| LTM Mar 2026 | $48.53M | +281.7% | — | 15.4% | |
| LTM Mar 2026 | $36.26M | -23.7% | -15.4% | 8.5% | |
| Peer median (excluding SION) | $116.61M | +32.1% | +26.7% | 110.8% | |
Competitors are the stored peer set for SION. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Sionna Therapeutics, Inc.
NASDAQ:SION
Intrinsic Alpha fair value
Locked
Current Price
$2.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.